Renovion and the COPD Foundation have announced the initiation of a Phase 2 trial of Renovion’s ARINA-1 nebulized glutathione / bicarbonate / ascorbic acid in patients with non-CF bronchiectasis (NCFBE). The COPD Foundation announced in September 2021 that it was partnering with Renovion on development of ARINA-1 for the treatment of COPD and NCFBE. The company is also developing ARINA-1 for the prevention of bronchiolitis obliterans in bilateral lung transplant patients.
Renovion Chief Scientific Officer Carolyn Durham said, “ARINA-1 has been shown to have significant mucolytic activity, as well as robust anti-inflammatory properties. Mucus and inflammation are hallmarks of NCFBE, and by directly targeting mucus and inflammation with a therapy nebulized directly to the airway, ARINA-1 has the potential to change the course of disease for these patients and alleviate mucus symptoms. Currently, there are no FDA-approved therapies for treating NCFBE and its associated mucus symptoms.”
COPD Foundation Chief Scientific Officer Bruce Miller commented, “As a partner with Renovion through our therapeutics and digital health accelerator 360Net, we’re pleased to see that the ARINA-1 Phase 2 clinical study has its first patient enrolled. Many patients in our bronchiectasis and COPD communities struggle on a daily basis with mucus production and chronic inflammation (commonly referred to as chronic bronchitis). New therapies that improve mucus clearance can ultimately improve a patient’s quality of life.”
Read the Renovion press release.
